成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Accounts of Chemical Research >>article
Accounts of Chemical Research

Accounts of Chemical Research

IF: 16.39
Download PDF

Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.

Published:1 March 2014 DOI: 10.1007/s00380-013-0340-3 PMID: 23559359
Masatsugu Hori, Ryozo Nagai, Tohru Izumi, Masunori Matsuzaki

Abstract

Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % ± 8.6 % vs 10.1 % ± 10.5 %), LV end-diastolic volume (-37.5 ± 48.7 vs -24.7 ± 29.4 ml), and LV end-systolic volume (-41.9 ± 43.0 vs -29.3 ± 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Carvedilol 72956-09-3 C24H26N2O4 618 suppliers $20.00-$700.00
Bisoprolol fumarate 104344-23-2 C22H35NO8 581 suppliers $28.00-$925.00
BISOPROLOL FUMARATE 105878-43-1 C22H35NO8 4 suppliers $25.00-$113.00
BISOPROLOL FUMARATE 66722-45-0 C22H35NO5 4 suppliers Inquiry

Similar articles

IF:10.5

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

JAMA Network Open Katherine L. Modzelewski, Alexandra Pipilas,etc Published: 2 May 2024
IF:3

Unlocking the Potential of Acetazolamide: A Literature Review of an Adjunctive Approach in Heart Failure Management

Journal of Clinical Medicine Michael Sabina, Zein Barakat,etc Published: 4 January 2024